LENZ Therapeutics
LENZ
65 hedge funds and large institutions have $327M invested in LENZ Therapeutics in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 5 reducing their positions, and 9 closing their positions.
440% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 5
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
18% more funds holding
Funds holding: 55 → 65 (+10)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
10% less capital invested
Capital invested by funds: $362M → $327M (-$35M)
120.99% less ownership
Funds ownership: 195.08% → 74.08% (-121%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.1M |
| 2 |
BlackRock
New York
|
+$12.6M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.75M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.49M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$3.01M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$830K |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
-$703K |
| 4 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$209K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$131K |
LENZ Hedge Fund Activity: Q2 2024 in Review
65 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2024, worth a combined $327M — down 9.7% from $362M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new LENZ positions and 9 closed out — a net gain of 10 holders — while 27 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $13.1M. The largest seller was Jennison Associates, exiting entirely with an estimated $3.01M sold.
- 65 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2024, up from 55 in Q1 2024.
- Funds reported $327M of LENZ Therapeutics stock for Q2 2024, down 9.7% quarter-over-quarter.
- 19 funds opened new LENZ Therapeutics positions in Q2 2024 and 9 closed out, a net change of +10 holders.
- The largest LENZ Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $13.1M added.
- The largest LENZ Therapeutics seller in Q2 2024 was Jennison Associates, an estimated $3.01M sold.
Based on aggregated 13F filings for Q2 2024.